Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
The government’s Regulatory Reform Council submitted a recommendation paper on May 19, calling for launching discussions in the current fiscal year to ease current restrictions on the exports of plasma products, saying that it wants a conclusion by FY2018. The…
To read the full story
Related Article
- MHLW to Gauge Possible Deregulation of Plasma Export Restriction towards FY2018: Blood Division Chief
August 3, 2016
- 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
April 4, 2016
- Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
- Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
REGULATORY
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Launches Task Force to Secure Critical Supplies amid Middle East Crisis
April 3, 2026
- MHLW Streamlines Lot Release Procedures for Vaccines, Blood Products
April 3, 2026
- MHLW Allows Outer Packaging Labeling for Regenerative Medicine Products
April 3, 2026
- MHLW’s Drug Supply Monitoring System Now Up and Running
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…